Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered its oncology pipeline through the acquisition of Modifi Biosciences, Inc., a biotechnology company specializing in direct DNA modification-enabled cancer therapeutics. This strategic move provides MSD with preclinical compounds aimed at exploiting DNA repair defects in hard-to-treat cancers. The acquisition deal includes a USD 30 million upfront payment and the potential for milestone payments that could total up to USD 1.3 billion.
Modifi Biosciences, established in 2021 and based on technology originated from Yale University, has developed a novel class of small molecules that specifically target cancer cells with a deficiency in the expression of a critical DNA repair protein, O6-methylguanine methyl transferase (MGMT). This innovative approach holds promise for advancing cancer treatments and addressing unmet medical needs in oncology.- Flcube.com
